SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · C4 Therapeutics has dosed the first patient in a Phase 1b trial…

C4 Therapeutics, Inc. · PRESS-RELEASE filed Mar 25, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 25, 2026 at 07:00 ET

C4 Therapeutics has dosed the first patient in a Phase 1b trial combining its investigational drug cemsidomide with Pfizer's FDA-approved elranatamab for relapsed/refractory multiple myeloma. The trial aims to evaluate safety and preliminary efficacy, with data expected in mid-2027, representing a strategic step in advancing cemsidomide across multiple treatment lines.

  • First patient dosed in a Phase 1b trial combining cemsidomide with elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma (RRMM).
  • Trial will evaluate cemsidomide at 50 µg, 75 µg, and 100 µg doses in combination with elranatamab; up to 54 patients to be enrolled.
  • Primary endpoint is safety and tolerability; secondary endpoints include overall response rate, MRD-negative complete response, and duration of response.
  • Pfizer is providing elranatamab at no cost under a clinical trial collaboration agreement; C4T is sponsoring and conducting the trial.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access